Losartan/hydrochlorothiazide Aurovitas 100 mg/25 mg film-coated tablets EFG

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Losartan/Hydrochlorothiazide Aurovitas 100 mg/25 mg film-coated tablets EFG

Losartan potassium and hydrochlorothiazide

Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

1. What Losartan/Hydrochlorothiazide Aurovitas is and what it is used for
2. What you need to know before taking Losartan/Hydrochlorothiazide Aurovitas
3. How to take Losartan/Hydrochlorothiazide Aurovitas
4. Possible side effects
5. How to store Losartan/Hydrochlorothiazide Aurovitas
6. Contents of the pack and other information

1. What Losartán/Hidroclorotiazida Aurovitas is and what it is used for

Losartán/Hidroclorotiazida Aurovitas is a combination of an angiotensin II receptor antagonist (losartán) and a diuretic (hydrochlorothiazide).

Angiotensin II is a substance produced in the body that binds to receptors present in blood vessels, causing them to narrow. This results in increased blood pressure. Losartán prevents angiotensin II from binding to these receptors, leading to relaxation of the blood vessels, thereby reducing blood pressure. Hydrochlorothiazide causes the kidneys to eliminate larger amounts of water and salts. This also helps lower blood pressure.

This medicine is indicated for the treatment of essential hypertension (high blood pressure).

2. What you need to know before taking Losartán/Hidroclorotiazida Aurovitas

Do not take Losartán/Hidroclorotiazida Aurovitas

• if you are allergic to losartan, hydrochlorothiazide, or any of the other ingredients of this medicine (listed in section 6),
• if you are allergic to other sulfonamide-derived substances (e.g. other thiazides, certain antibiotics such as cotrimoxazole; ask your doctor if you are unsure),
• if you are more than 3 months pregnant. It is also preferable to avoid Losartán/Hidroclorotiazida Aurovitas in early pregnancy (see section Pregnancy),
• if you have severe liver impairment,
• if you have severe renal impairment or your kidneys are not producing urine,
• if you have low levels of potassium or sodium or high levels of calcium that cannot be corrected with treatment,
• if you suffer from gout,
• if you have diabetes or kidney impairment and are being treated with a blood pressure-lowering medicine containing aliskiren.

Warnings and precautions

Consult your doctor or pharmacist before taking Losartán/Hidroclorotiazida Aurovitas:

• If you have had skin cancer or develop an unexpected skin lesion during treatment. Treatment with hydrochlorothiazide, particularly long-term use at high doses, may increase the risk of certain types of non-melanoma skin cancer and lip cancer. Protect your skin from exposure to sunlight and UV rays while taking losartan/hydrochlorothiazide.

• If you experience a decrease in vision or eye pain, which could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or increased intraocular pressure, potentially occurring within hours to weeks after taking this medicine. Without treatment, this may lead to permanent vision loss. If you have previously had an allergy to penicillin or sulfonamides, you may be at higher risk.

• If you have previously experienced respiratory or lung problems (such as inflammation or fluid in the lungs) after taking hydrochlorothiazide. If you develop dyspnea or severe difficulty breathing after taking losartan/hydrochlorothiazide, seek medical attention immediately.

You should inform your doctor if you think you are pregnant (or could be). Losartán/Hidroclorotiazida Aurovitas is not recommended during early pregnancy and must not be used if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at this stage (see section Pregnancy).

It is important to inform your doctor before taking Losartán/Hidroclorotiazida Aurovitas:

• if you have previously experienced swelling of the face, lips, tongue, or throat,
• if you are taking diuretics (medicines to increase urine production),
• if you are on a low-salt diet,
• if you have had excessive vomiting and/or diarrhea,
• if you have heart failure,
• if your liver function is impaired (see section 2 ‘Do not take Losartán/Hidroclorotiazida Aurovitas’),
• if you have narrowing of the arteries supplying the kidneys (renal artery stenosis), if you only have one functioning kidney, or if you have recently undergone a kidney transplant,
• if you have narrowing of arteries (atherosclerosis), angina pectoris (chest pain due to poor heart function),
• if you have aortic or mitral valve stenosis (narrowing of heart valves) or hypertrophic cardiomyopathy (a condition causing thickening of the heart muscle),
• if you are diabetic,
• if you have had gout,
• if you have or have had an allergic disorder, asthma, or a condition causing joint pain, skin rashes, and fever (systemic lupus erythematosus),
• if you have high calcium levels or low potassium levels, or if you are on a low-potassium diet,
• if you require anesthesia (even at the dentist) or prior to surgery, or if you are undergoing tests to assess parathyroid function, you must inform your doctor or healthcare provider that you are taking losartan potassium and hydrochlorothiazide tablets,
• if you have primary hyperaldosteronism (a syndrome associated with excessive secretion of the hormone aldosterone by the adrenal gland due to gland dysfunction),
• if you are taking any of the following medicines used to treat high blood pressure (hypertension):
• an angiotensin-converting enzyme (ACE) inhibitor (e.g. enalapril, lisinopril, ramipril), especially if you have kidney problems related to diabetes,
• aliskiren.

Your doctor may regularly monitor your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium).

See also the information under the heading “Do not take Losartán/Hidroclorotiazida Aurovitas”.

• if you are taking other medicines that may increase serum potassium (see section 2 “Other medicines and Losartán/Hidroclorotiazida Aurovitas”).

Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking losartan/hydrochlorothiazide. Your doctor will decide whether to continue treatment. Do not stop taking losartan/hydrochlorothiazide on your own.

Children and adolescents

There is no experience with the use of Losartán/Hidroclorotiazida Aurovitas in children. Therefore, Losartán/Hidroclorotiazida Aurovitas must not be administered to children.

Other medicines and Losartán/Hidroclorotiazida Aurovitas

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Diuretics such as hydrochlorothiazide contained in Losartán/Hidroclorotiazida Aurovitas may interact with other medicines.

Inform your doctor if you are taking potassium supplements, salt substitutes containing potassium, potassium-sparing medicines, or other medicines that may increase serum potassium (e.g. medicines containing trimethoprim), as combination with losartan/hydrochlorothiazide is not recommended.

Lithium-containing preparations must not be taken with losartan/hydrochlorothiazide unless your doctor performs careful monitoring.

Special precautions (e.g. blood tests) may be appropriate if you are taking diuretics (water tablets), certain laxatives, medicines for gout, medicines to control heart rhythm, or medicines for diabetes (oral medicines or insulin).

It is also important that your doctor knows if you are taking:

• other medicines to lower your blood pressure,
• steroids,
• medicines to treat cancer,
• pain medicines,
• medicines to treat fungal infections,
• medicines for arthritis,
• cholesterol-lowering resins such as cholestyramine,
• muscle relaxants,
• sleeping tablets,
• opioid medicines such as morphine,
• "vasopressor amines" such as adrenaline or other medicines in the same group,
• oral medicines for diabetes or insulin.

Your doctor may need to adjust your dose and/or take other precautions:

• if you are taking an angiotensin-converting enzyme (ACE) inhibitor or aliskiren (see also information under the headings “Do not take Losartán/Hidroclorotiazida Aurovitas” and “Warnings and precautions”).

Please inform your doctor when you plan to undergo iodinated contrast media procedures while taking Losartán/Hidroclorotiazida Aurovitas.

Taking Losartán/Hidroclorotiazida Aurovitas with food, drinks, and alcohol

You are advised not to drink alcohol while taking these tablets: alcohol and losartan/hydrochlorothiazide tablets may increase each other's effects.

Excessive dietary salt intake may counteract the effect of losartan/hydrochlorothiazide tablets.

Losartán/Hidroclorotiazida Aurovitas may be taken with or without food.

Grapefruit juice should be avoided while taking Losartán/Hidroclorotiazida Aurovitas.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

Pregnancy You should inform your doctor if you think you are pregnant (or could be). Your doctor will usually advise you to stop taking losartan and hydrochlorothiazide before becoming pregnant or as soon as you know you are pregnant, and will recommend an alternative medicine. Losartan and hydrochlorothiazide are not recommended during pregnancy and must not be taken if you are more than 3 months pregnant, as they may cause serious harm to your baby if used from the third month of pregnancy onward.

Breastfeeding Inform your doctor if you are breastfeeding or about to start breastfeeding. Losartán/Hidroclorotiazida Aurovitas is not recommended for breastfeeding mothers, and your doctor may choose an alternative treatment if you wish to breastfeed.

Use in elderly patients

Losartán/Hidroclorotiazida Aurovitas is equally effective and well tolerated in most elderly and younger patients. Most elderly patients require the same dose as younger patients.

Driving and using machines

When starting treatment with this medicine, do not perform tasks requiring special attention (e.g. driving a car or operating dangerous machinery) until you know how you react to the medicine.

Losartán/Hidroclorotiazida Aurovitas contains lactose

This medicine contains lactose. If your doctor has informed you that you have an intolerance to certain sugars, consult him before taking this medicine.

3. How to take Losartan/Hydrochlorothiazide Aurovitas

Follow exactly the instructions for using this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Your doctor will determine the appropriate dose of losartan and hydrochlorothiazide based on your condition and whether you are taking other medicines. It is important to continue taking losartan and hydrochlorothiazide as prescribed by your doctor to maintain consistent blood pressure control.

This medicine is available in three strengths: 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg.

High blood pressure

For most patients with high blood pressure, the recommended dose is 1 tablet of losartan and hydrochlorothiazide 50 mg/12.5 mg once daily to control blood pressure over 24 hours. The dose may be increased to 2 film-coated tablets of 50 mg/12.5 mg daily or changed to 1 film-coated tablet of 100 mg/25 mg (a stronger dose) daily. The maximum daily dose is 2 film-coated tablets of 50 mg/12.5 mg daily or 1 film-coated tablet of 100 mg/25 mg daily.

Method of administration

Losartan/Hydrochlorothiazide Aurovitas tablets should be swallowed whole with a glass of water.

If you take more Losartan/Hydrochlorothiazide Aurovitas than you should

In case of overdose, contact your doctor immediately to receive immediate medical attention. Overdose may cause low blood pressure, palpitations, slow pulse, changes in blood composition, and dehydration. In the event of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at telephone number: 91 562 04 20, indicating the medicine and the amount ingested.

If you forget to take Losartan/Hydrochlorothiazide Aurovitas

Try to take losartan/hydrochlorothiazide daily as prescribed. However, if you miss a dose, do not take an extra dose. Simply return to your regular schedule. Do not take a double dose to make up for a missed dose.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them.

If you experience the following, stop taking Losartan/Hydrochlorothiazide Aurovitas tablets and contact your doctor immediately or go to the nearest hospital emergency department:

• A severe allergic reaction (skin rash, itching, swelling of the face, lips, mouth or throat, which may cause difficulty swallowing or breathing).

This is a serious but rare adverse effect, affecting more than 1 in 10,000 patients but fewer than 1 in 1,000. It may require urgent medical attention or hospitalization.

The following adverse effects have been reported:

Common (may affect up to 1 in 10 people):

• Cough, upper respiratory tract infection, nasal congestion, sinusitis, sinus disorder,
• diarrhoea, abdominal pain, nausea, indigestion,
• muscle pain or cramps, leg pain, back pain,
• insomnia, headache, dizziness,
• weakness, fatigue, chest pain,
• elevated potassium levels (which may cause abnormal heart rhythm), decreased haemoglobin levels,
• changes in kidney function including renal failure,
• blood sugar too low (hypoglycaemia).

Uncommon (may affect up to 1 in 100 people):

• Anaemia, red or brown spots on the skin (sometimes especially on feet, legs, arms and buttocks, with joint pain, swelling of hands and feet and abdominal pain), bruising, reduction in white blood cells, bleeding disorders, reduced platelet count,
• loss of appetite, elevated uric acid levels or overt gout, elevated blood glucose levels, abnormal blood electrolyte levels,
• anxiety, nervousness, panic disorders (recurrent panic attacks), confusion, depression, abnormal dreams, sleep disorders, somnolence, memory impairment,
• muscle aches or similar sensations, limb pain, tremor, migraine, fainting,
• blurred vision, burning or pricking sensations in the eyes, conjunctivitis, worsening of vision, seeing things in yellow,
• ringing, buzzing, noise or crackling in the ears, vertigo,
• low blood pressure which may be associated with postural changes (feeling dizzy or weak when standing up), angina (chest pain), abnormal heartbeats, stroke (transient ischaemic attack, "mini-stroke"), heart attack, palpitations,
• inflammation of blood vessels often associated with a skin rash or bruising,
• sore throat, shortness of breath, bronchitis, pneumonia, fluid in the lungs (causing difficulty breathing), nosebleed, runny nose, congestion,
• constipation, chronic constipation, flatulence, stomach disorders, stomach spasms, vomiting, dry mouth, inflammation of a salivary gland, toothache,
• jaundice (yellowing of eyes and skin), inflammation of the pancreas,
• urticaria, itching, skin inflammation, rash, skin redness, photosensitivity, dry skin, flushing, sweating, hair loss,
• pain in arms, shoulders, hips, knees or other joints, joint swelling, stiffness, muscle weakness,
• frequent urination even during the night, abnormal kidney function including kidney inflammation, urinary tract infection, sugar in urine,
• decreased sexual appetite, impotence,
• facial swelling, localized swelling (oedema), fever.

Rare (may affect up to 1 in 1,000 people):

• Hepatitis (inflammation of the liver), abnormal liver function tests.
• Intestinal angioedema: swelling in the intestine presenting with symptoms such as abdominal pain, nausea, vomiting and diarrhoea.

Very rare (may affect up to 1 in 10,000 people):

• Acute breathing difficulty (symptoms include severe breathlessness, fever, weakness and confusion).

Frequency not known (cannot be estimated from the available data):

• Flu-like symptoms,
• muscle pain of unknown origin with dark-coloured urine (tea-coloured) (rhabdomyolysis),
• low sodium levels in blood (hyponatraemia),
• generally feeling unwell (malaise),
• altered taste (dysgeusia),
• skin and lip cancer (non-melanoma skin cancer),
• sudden decrease in distance vision (acute myopia), decreased vision or eye pain due to high intraocular pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Losartan/Hydrochlorothiazide Aurovitas

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging/label. The expiry date is the last day of the month indicated.

Store below 25°C.

Medicines should not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at a pharmacy’s SIGRE Point. Ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Losartan/Hydrochlorothiazide Aurovitas

• The active substances are losartan potassium and hydrochlorothiazide.

Losartan/Hydrochlorothiazide Aurovitas 100 mg/25 mg tablets contain 100 mg of losartan potassium and 25 mg of hydrochlorothiazide as active substances.

• The other components are:

Tablet core: microcrystalline cellulose, monohydrate lactose (lactose), pregelatinized corn starch (corn starch), colloidal anhydrous silica, magnesium stearate.

Tablet coating: hydroxypropyl cellulose (E463), hypromellose 6cP (E464), titanium dioxide (E171), quinoline yellow aluminium lake (E104).

Nature of the product and contents of the container

Film-coated tablet.

Film-coated, yellow, oval-shaped tablets with bevelled edges, biconvex, engraved with 'E' on one side and '49' on the other.

Losartan/Hydrochlorothiazide Aurovitas film-coated tablets are available in opaque white PVC/PE/PVDC - aluminium foil blisters and high-density polyethylene (HDPE) bottles with polypropylene caps.

Pack sizes:

Blisters: 14, 28, 30, 50, 56, 60, 90, 98, 100, 280 and 500 film-coated tablets.
Bottles: 14 and 500 film-coated tablets.

Only certain pack sizes may be marketed.

Marketing Authorization Holder

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid

Spain

Manufacturer

APL Swift Services (Malta) Limited

HF26, Hal Far Industrial Estate, Hal Far

Birzebbugia, BBG 3000

Malta

This medicinal product is authorized in the European Economic Area (EEA) member states under the following names:

Spain: Losartán/Hidroclorotiazida Aurovitas 100 mg/25 mg film-coated tablets EFG

Malta: Losartan /Hydrochlorothiazide Aurobindo 100 mg/25 mg film-coated tablets

Portugal: Losartan + Hidroclorotiazida Aurovitas

Date of the most recent revision of this leaflet: August 2025

Detailed information on this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).